Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AEZS/KERX. Article link .FDA Approval Pratically A Done Deal For Keryx And AEterna Zentaris. (no position currently Careful chasing in the AH they spiked already, I would wait for a pullback. imo).
http://seekingalpha.com/article/408841-fda-approval-pratically-a-done-deal-for-keryx-and-aeterna-zentaris?source=kizur
EGT: Entertainment Gaming Asia. New pics.
http://www.elixirgaming.com/CasinoPailin_2012-02.html
NOTE: Earnings CC and live webcast on 3/8/2012.
Thanks for your feedback i also still in!
Optimistic article on AFFY
http://finance.yahoo.com/news/affymax-rises-analyst-view-anemia-180307883.html
DNDN--holding 95% of my original shares---not something to brag about, from as far back as 2001.
New CEO, new focus on lowering COG, expected greater usage by large urology groups as they get comfortable with reimbursement and administration of drug.
New 2-3 quarters are KEY to regain revenue growth and Wall Street's confidence. I am holding and buying under $11.
$DNDN - Interesting SA - Why I Remain Positive On Dendreon
http://seekingalpha.com/article/407861-why-i-remain-positive-on-dendreon
GRVY..$2.62 Just because SA article does not mean GRVY will move. They promised shareholders they would deliver on a specific date and failed on that promise. It was a trade with potential that still has potential if the CEO steps up. I am leery until I see different. Good luck.
TLON..$.86 This is the data from the RALLY study that the FDA will be reviewing at the Advisory Panel Mtng. I believe that Dr. Susan O'Brien, M.D. Anderson, will be present to make a strong case for Marqibo approval. Advisory Panels are always risky and can make or break a stock most of the time. I am a risk taker and like what I have seen from Talon which is why I will continue to hold my position. I don't have a large position but will add if I like the AdCom notes and definitely if there is a positive panel review. If a positive review, then chance for approval is much greater. Two more weeks left till the notes are released. To invest a lot of money just for risk sake is not a wise move. Invest here what you can afford to lose but don't swing for the fences without all the information to increase the odds of success. A small position (what you can afford to lose) is always best. For larger there are other biotech plays to put more money into with less risk. Just my two cents there. The reward is high here but also the risk. Big money with Warburg Pincus & Deerfield is in this company & I like that. I would like to see a patient enrolled in the confirmatory Phase III study (MARQIBO) as well before the AdCom Mtng. That would be a huge plus for Talon as well as members of ODAC. Talon has increased the enrollment sites but they are just waiting for that patient. Hard to find in 3rd-6th line which is why it is viewed by FDA as rare & unmet need. The trial is initiated so that is a positive but patient enrollment would be huge.
I will continue to post solid DD over next few weeks on this company moving forward so that one can make a best case decision based on the DD.
http://files.shareholder.com/downloads/HNAB/1689720077x0x527738/52FECA95-2084-4153-9AA8-7BD84FD3FCA8/ASH_poster_2011v2_final.pdf
RGEN..$4.66 Good report from LifeSci Advisors from 2/28. Has some good in depth information on the company.
http://bit.ly/
GRVY: via SeekingAlpha.
Imo, this is going to get big play.
Last SA moved it 50%.
http://seekingalpha.com/article/407471-gravity-has-game
PLX..$5.40 With a PDUFA date of May 1st, we know that it will start to catch fire here sooner rather than later. This price here continues to be attractive for entry.
RGEN..$4.66 Busted through $4.65 on low volume on a down market day. There had been a lot of resistance at that level so that is a positivel $5.00 is the next level I see ahead.
AFFY..$10.79 Almost crossed $11 today. With 3 wks left till their PDUFA, the volume has been strong the past few months.
$GTXI - massive block @ 3.30, 200k + shares...I continue to nibble in anticipation of Ostarine approval. Citi valued Ostarine alone @ $11/shr.
RENN pre-market is on fire.
http://ih.advfn.com/p.php?pid=nmona&article=51454554&symbol=RENN
gl
trip advisor is another web based review site for people to hammer or praise your business without any recourse.
why yelp will fail is they have a filtration system that almost knocks off every positive review your business gets unless its from a contributer that has multiple reviews.
then they email you every week with a "this is how many page views your business had WITHOUT advertising...
its a scam
unfortunately, the hedge funds will own all the short shares much like they do with groupon....so reatil wont be able to get in on the feed...
here is an example of trip advisor and a little spam :) much more objective and this is why IMHO they will bury yelp...
[url]http://www.tripadvisor.com/ShowUserReviews-g34675-d418168-r86559049-Cabo_s_Island_Grill_Bar-Tallahassee_Florida.html[/url
RGEN..$4.63 Traded 613,000 in volume for month of February. Traded 108,000 today on March 1st. Its already 1/5 of the way to the total volume of February. Once this gets volume it will break its 52wk high of $4.91 rather easily and get to $6 in no time. March should be a solid month as the volume continues to move higher.
What do you mean trip advisor is one, just curious.
was not very impressed with groupon, though yelp may be target for a good short. but like the long term potential.
Its going to be interesting how Goldman plays there 1.1 million shares! Its an interesting arrangement.
gl
i own an restaurant and can honestly say yelp is a scam.
trip advisor is the one. urban spoon #2
its too bad there will be no shares to short.
there were none for groupon either. another scam that cant find business to do it twice because its a rip off too
could of retired shorting groupon .such sure thing.
same thing is going to happen with yelp. watch
YELP:
http://dealbook.nytimes.com/2012/03/01/yelp-prices-its-offering-at-15-a-share/
should be interesting opening.
Yelp Prices Its Offering at $15 a Share
By EVELYN M. RUSLI
Spencer Platt/Getty ImagesYelp’s market debut will be another critical test of investor appetite for technology stocks.
Yelp, the online hub for local business reviews, priced its initial public offering at $15 a share on Thursday, above its expected range, according to people briefed on the matter.
At that price, the company has raised $107.25 million, at a $898.1 million valuation. Its market debut, set for Friday morning, will be another critical test of investor appetite for technology stocks, ahead of Facebook’s multibillion-dollar I.P.O. expected later this year.
At a market value of $898.1 million. Yelp will be trading at a high multiple, at more than 10 times revenue. Still, the valuation is slightly lower than earlier estimates, reflecting concerns about the market and Yelp’s business model. The start-up, which attracts some 66 million users per month, has a huge inventory of local business pages and user-generated reviews, spanning markets in North America, Western Europe and Australia. The service is free for consumers but local businesses pay to advertise on the site and to add premium features to their Yelp pages.
In 2011, the company generated $83.3 million in revenue and a net loss attributable to common shareholders of $16.9 million.
And that’s the rub with Yelp. Founded in 2004 in San Francisco, the company is still not profitable.
In its most recent prospectus, the company acknowledged that it has “incurred significant operating losses” and warned that its revenue growth will slow as its business matures, while its costs are expected to increase. A lack of profits is far from an anomaly in the Internet sector, but Yelp is facing increasing pressure from upstarts and giants like Google. The Internet company — which has, at times, prioritized its content over Yelp’s– recently bought Zagat, another popular aggregator of reviews and business ratings. In its filing, Yelp noted that Google is its “most significant source of traffic.”
Though demand is expected to be high for Yelp’s debut, many investors are still skeptical.
“The revenues are excellent right now, but their losses are high,” said Scott Sweet, a managing partner of IPOboutique.com, an I.P.O. advisory firm. “My primary concern is the current competition and the new players that will enter this space.”
The equity markets have been choppy for technology offerings, though more stable compared to the second half of last year. On Thursday, GCT Semiconductor, a maker of wireless chips, postponed its offering.
Meanwhile, Demandware, an enterprise software business, pushed ahead with its I.P.O. plans, setting its price target at $12.50 to $14.50 per share, putting it on track to raise about $74 million at the mid-point of the range. Angie’s List, another online reviews site that went public last November, rose nearly 1 percent on Thursday to close at $16.12, about 24 percent above its offering price.
Yelp’s largest shareholders, including Jeremy Stoppelman, the company’s chief executive, will not sell any shares in the offering. The sole entity selling shares is the Yelp Foundation, the company’s nonprofit arm, which plans to sell 50,000 shares in the I.P.O. Yelp’s largest venture capital backers, Bessemer Venture Partners, Elevation Partners and Benchmark Capital Partners, own roughly 60 percent of the company, with Bessemer and Elevation each holding a 22 percent stake.
According to its prospectus, Yelp plans to use the proceeds from the I.P.O. for general expenses, including sales and marketing activities, and for acquisitions or technologies that complement its business.
Its shares will trade on the New York Stock Exchange under the ticker “YELP.”
For its offering, Yelp is selling 7.15 million shares. But its underwriters, led by Goldman Sachs, Citigroup and Jefferies, have the option to sell an additional 1.1 million shares, based on demand.
gl
TBOW: Heads up .Possible breakout.
Over 2.00 now.
Gonna hit some screens.
RGEN..$4.55 Many Upcoming Expected Milestones in 2012. Market cap of only 140m Will be a busy year for them & should continue to be a good year for the stock. Bolded the two most crucial milestones.
Near-Term Milestones
- 1Q 2012 – Submit SecreFlo™ Marketing Authorization Application in Europe
- 1Q 2012 – Enroll first patient in RG2833 Friedreich’s ataxia Phase I study in Italy
- 2Q 2012 – Interim data on SecreFlo™ pilot study to improve diagnosis of pancreatic cancer
- 2Q 2012 – Complete integration of Novozymes Biopharma AB
- 2Q 2012 – Report results of RG3039 Phase I study for Spinal Muscular Atrophy
- 2Q 2012 – Present SecreFlo™ Phase III data at Digestive Disease Week (DDW)
- June 21, 2012 – SecreFlo™ PDUFA date with priority review
- 2H 2012 – Launch SecreFlo™ in the US pending FDA approval
- 2H 2012 – Initiate pediatric studies of SecreFlo™
Company has zero debt & 50m in cash. $1.62 cash per share & $2.21 book value per share. Only 30m shares outstanding and only 40m authorized. Little chance of dilution and if so it can only be to 40m unless authorized by board of directors to increase the authorized. Only 26m shares in the float. Almost 40% held by institutions. 3m avg volume of only 35,000 shares. This should get more attention in the coming months.
Clinical Basis for SecreFlo™ NDA
The SecreFlo™ NDA was submitted to the FDA based on positive outcomes from the re-read of the Company’s Phase 3 clinical study. This pivotal study was a multi-center, baseline controlled, single dose study in which 258 patients were enrolled at 23 clinical sites in the U.S. and Canada. Each patient
in the study received an MRI of the pancreas with and without SecreFlo™, and separately underwent endoscopy (ERCP) as a diagnostic reference. The MRI images were randomized and independentlyread and reviewed by three central radiologists.
The Phase 3 study re-read demonstrated that all endpoints were met with statistical significance, and that SecreFlo™ was safe and well tolerated. The study’s co-primary endpoints were achievement of a statistically significant improvement in sensitivity of detection of abnormalities of the pancreatic ducts
with minimal loss in specificity by two of the three central radiologists reading the MRI images. The study met its primary endpoints, demonstrating that the addition of SecreFlo™ to MRI resulted in a highly statistically significant improvement (p<0.0001) in sensitivity of detection of ten prespecified
abnormalities of the pancreatic ducts, with minimal loss in specificity (<7.5%). All three secondary endpoints were also met, with each demonstrating highly statistically significant improvements (p<0.0001) in image quality, visualization of the main pancreatic duct and diagnostic confidence when compared to MRI alone. A radiologist’s ability to more confidently identify and characterize pancreatic duct abnormalities has the potential to substantially improve “next-step” clinical decisions
(patient triage) and patient outcomes. SecreFlo™ was previously granted Fast Track designation by the FDA and also has Orphan Drug
status, which qualifies Repligen to receive seven years of U.S. marketing exclusivity for SecreFlo™, if approved. In addition to it’s U.S. application for approval of SecreFlo™, the Company plans to file a marketing authorization application (MAA) during the first quarter of 2012 for potential approval of SecreFlo™ in the EU.
ALXA..$.63 One I am keeping an eye on even if it is just for a potential trade into their PDUFA date. I don't own any of it. Been watching the Form 4's. Even though the buying is indirect, it has been consistent in the .50 cent range.
ALXA
Any thoughts on this one going forward $heff? Looking at your past trades it looks like you liked it at one point but took a small loss on it.
The advisory panel voted in favor of approval back in December. There is some internal turmoil within the company with directors leaving and staff being laid off.
EXAS..$9.40 Continues to be a solid performer since beginning of the year. Started the year around $8/share.
$CIGX Star Scientific Announces Notice Of Allowance By US PTO Granting New Patent Claims Relating To Tobacco Curing Technology >CIGX
http://www.dailymarkets.com/stock/2012/03/01/star-scientific-announces-notice-of-allowance-by-us-pto-granting-new-patent-claims-relating-to-tobacco-curing-technology/
RGEN..$4.49 Moving higher here on low volume again. This has not had its run since receiving priority approval for their drug. It will move higher on low volume each day.
Repligen announced that the FDA has accepted for filing and granted Priority Review to the co's new drug application for SecreFlo for the improved detection of pancreatic duct abnormalities in patients with pancreatitis (RGEN) 4.21 : Under the Prescription Drug User Fee Act (PDUFA), the FDA's goal for completing a Priority Review and delivering a decision on marketing approval is reduced to six months, compared to ten months for a Standard Review. The FDA has assigned a PDUFA goal date of June 21, 2012 to the SecreFlo NDA.
AFFY..$10.30 Solid PDUFA play. Company is under $400m market cap with 115m in cash. Company de-risking from the AdCom Panel with a 15-1 vote in favor. Should be trading close to $12 before PDUFA date & undervalued at the current level IMO.
Check out MOD, Modine Mfg. Huge contracts with CAT and extremely undervalued.
ONXX..$38.32 Target enrollment reached for the ASPIRE trial, evaluating carfilzomib + lenalidomide/ dexamethasone in pts with relapsed multiple myeloma. (Medscape Oncology)
PFE..$21.10 & BMY..$32.29 FDA extends Eliquis PDUFA date for atrial fibrillation/stroke prevention by 3 months. The new PDUFA date is June 28th, 2012. No Advisory Panel meeting has been scheduled.
http://finance.yahoo.com/news/u-food-drug-administration-extends-030100167.html
OT: FDA announces safety changes in labeling for some cholesterol-lowering drugs http://1.usa.gov/xmkEwx
Bayer, J&J clot drug to get fast FDA review for ACS: Reuters Tue, 02/28/12 http://dlvr.it/1FwctL
SLXP $49.32 On 2/28 Auriga ups from Hold to Buy w/ $55 target.
Why No Obesity Drug Will Ever Be The Next Lipitor - Forbes http://onforb.es/x8qMX8 VVUS, ARNA, & OREX
OT: George Sledge on the science of insomnia. (Good article) http://bit.ly/wB5DDt
BIIB..$116.79 FDA approves AVONEX® PEN and dose titration regimen. http://finance.yahoo.com/news/FDA-Approves-AVONEX-PEN-Dose-bw-79320495.html
BDSI..$2.26 and FDA reach agreement on BEMA Buprenorphine/Naloxone (BNX) development plan. http://bit.ly/zGEs7v
OT: Fake Avastin contained salt, strach and chemicals used in animal feed, and no active drug at all, according to Genentech. (Medscape Oncology).
AMRN - what a day for trading this stock. Amarin Reports Fourth Quarter and Year-End 2011 Financial Results and Provides Update on Operations
Conference Call Set for 4:30 p.m. EST Today
GlobeNewswirePress Release: Amarin Corporation plc – 41 minutes ago
RELATED QUOTES
Symbol Price Change
AMRN 7.75 -0.98
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 29, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN - News), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced financial results for the quarter and year ended December 31, 2011 and provided an update on company operations.
Key Amarin accomplishments since the quarter ended September 30, 2011 include:
* Acceptance of AMR101 New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) and FDA assignment of Prescription Drug User Fee Act (PDUFA) date of July 26, 2012
* Strengthened balance sheet through successful completion of a $150M exchangeable note offering
* Commenced patient enrollment and dosing in the REDUCE-IT cardiovascular outcomes study
* Broadened management team with the addition of a General Counsel and a President of R&D
"In 2011, Amarin made important progress toward the development of, and commercial preparedness for, our lead product candidate, AMR101," said Joseph Zakrzewski, Chairman and Chief Executive Officer of Amarin. "In 2012 we are working vigorously to build on this progress and maximize the value of AMR101 as we advance toward the PDUFA date."
http://finance.yahoo.com/news/amarin-reports-fourth-quarter-end-210100913.html
ALXA,
Somebody wants shares of this stock.
On a down Market day,ALXA closed at .625,up 4.17%.
The stock is now above the downtrend line.
http://finviz.com/quote.ashx?t=alxa&ty=c&ta=1&p=d
Manny
BRIEF-Amarin updates on FDA advisory committee schedule in connection with NDA for AMR101
Feb 13 (Reuters) - Amarin Corp PLC <AMRN.O>:
* Announces FDA advisory committee will not be scheduled in connection with new
drug application for AMR101
* FDA had previously assigned pdufa date of July 26 2012 for completion of its
review of the AMR101 NDA
ALXA,
Up another 5% to .63.
Hopefully the chart players and investors see that ALXA is breaking out of downtrend channel,and this move higher continues.
http://finviz.com/quote.ashx?t=alxa&ty=c&ta=1&p=d
Manny
What is GREENVAX ? !!
http://www.pharmaceutical-technology.com/projects/thegreenvaxprojectte/
The GreenVax project aims to produce vaccines from the tobacco plant on a large-scale.
Financing
In February 2010, the GreenVax project received $40m funding from the Defense Advanced Research Projects Agency (DARPA) of the US Department of Defense. The public-private-partnership is largely financed by DARPA. The G-Con and A&M will fund $21m towards the project.
The development of the tobacco-based vaccine production technology was funded through the Texas Emerging Technology Fund. In August 2010, the project also received $4m funds from the Texas Military Preparedness Commission (TMPC).
"Licensing
The new GreenVax plant will be licensed by iBio Inc. The company will provide the iBioLaunch technology platform and provide technology transfer services to G-Con to be implemented in the Bryan facility. ( IBIO : Amex )
"
Future Link & Business News
http://www.finviz.com/futures.ashx
Economic Growth Jumps to 3%; Prices Post Big Gains
The U.S. economy grew a bit faster than initially thought in the fourth quarter on slightly firmer consumer and business spending, which could help to allay fears of a sharp slowdown in growth in early 2012.
http://www.cnbc.com/id/46570434
Dow Hits 13,000, But Markets Aren't in Clear Yet
Despite the Dow and S&P 500 hitting their highest levels since 2008, investors are likely to be on edge Wednesday.
http://www.cnbc.com/id/46561414
Bankrupt Kodak asks court to let it slash retirees' health benefits
A month after it filed for Chapter 11 bankruptcy protection, Eastman Kodak Co. asked a federal court Monday to allow it to cut health care benefits for thousands of retirees.
http://bottomline.msnbc.msn.com/_news/2012/02/27/10520431-bankrupt-kodak-asks-court-to-let-it-slash-retirees-health-benefits
Investor 100
IBIO Patent Issued on Fusion-Protein Vaccine Technology
iBio, Inc. (NYSE AMEX: IBIO) today announced issuance of a US patent covering the use of iBio's proprietary fusion-protein technology in combination with influenza virus antigens for vaccine product applications. The invention comprises the use of lichenase in an adjuvant-like role to improve the performance of vaccines. This approach was developed by the Fraunhofer USA Center for Molecular Biotechnology (FhCMB), iBio's research collaborator. The new patent is US Patent 8,124,103, entitled "Influenza Antigen, Vaccine Compositions, and Related Methods".
The vaccine industry is increasingly focused on the development of subunit vaccines. These subunit vaccines require use of components called adjuvants for improving their efficacy. Lichenase, when fused to antigens acts as an adjuvant and can improve the efficacy of vaccines. Fusion of lichenase to vaccine antigens can enhance duration of immune response, improve production economies and increase product stability. This approach could provide significant advantages over more conventional methodologies used to improve vaccine efficacy.
"We consider the issuance of this patent to be an important step in the expansion of opportunities in subunit vaccine development," said Vidadi Yusibov, Ph.D., one of the patent's inventors and Executive Director of FhCMB. "We previously published data demonstrating significant improvement in candidate vaccine performance in animal models when lichenase technology is employed with a range of target antigens, including antigens from plague, malaria, and human papilloma virus."
"While iBio's principal focus has been to optimize and commercialize our proprietary platform technology for broad commercial applications across the biologics field, we also have been bringing forward lichenase as a separate proprietary product platform to be licensed to enhance vaccine performance," said Robert B. Kay, Executive Chairman and CEO of iBio. "Based upon the results obtained in multiple animal studies and the formulation advantages of using a fusion protein, we believe there will be substantial commercial interest in lichenase as a proprietary approach for potent subunit vaccines."
This patent is an important addition to iBio's broader intellectual property portfolio that includes the clinical-stage iBioLaunch™ platform for vaccines and therapeutic products.
About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of vaccines and therapeutic proteins using transient gene expression in green plants. The technology has been applied successfully to proteins difficult or impossible to produce with other methods, as well as proteins representative most important classes of biologic pharmaceuticals. Advantages of the iBioLaunch platform over other systems include enablement of rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more; product entry that is unconstrained by traditional process patents; and significantly lower capital and operating costs for comparable production. Further information is available at: www.ibioinc.com.
About Fraunhofer USA Center for Molecular Biotechnology
Fraunhofer USA CMB, a division of Fraunhofer USA, Inc., is a not-for-profit research organization whose mission is to develop safe and effective vaccines targeting infectious diseases and autoimmune disorders. The Center conducts research in the area of plant biotechnology, utilizing new, cutting edge technologies to assist with the diagnosis, prevention and treatment of human and animal diseases. The Center houses individuals with expertise and excellence in plant virology, pathology, molecular biology, immunology, vaccinology, protein engineering, and biochemistry. Further information is available at www.fraunhofer-cmb.org.
GRVY: 2/29 Update from IR.
Dear XXXXXXXXXX
Thank you for your inquiry.
Since RO2 still has some technical errors (bugs) like many other games in the OBT stage, we may need some more time to fix them. Currently, we expect the launch date will be in March.
Again, I do know that our investors are waiting for news but we would like to disclose information when it is finalized. Your understanding is much appreciated.
Thank you.
Kind regards,
Yoon Joo Lee
IR Manager
Note: Above email redacted for privacy:
Follow Me on Twitter: http://twitter.com/SheffStation/
New Economy Portfolio: Larger Cap stocks for slower but more consistent gains. Some Longer-Term Plays (30-60 days maybe longer)
Beginner Portfolio: Scalp Plays & Low Float Biotechs for potential explosive Growth. Quick Turnover 1-30 days (smaller balance want aggressive growth)
Position Size: STARTER: (1-5% Portfolio Balance) SOLID: (6-10% Portfolio Balance) FULL : (11-20% Portfolio Balance)
NEW ECONOMY PORTFOLIO | Sell Date | Ticker | Buy PPS | Sell PPS | Gain/Loss | Notes | % + or - | ||
| |||||||||
|
| ||||||||
|
| | |||||||
|
| ||||||||
|
| | |||||||
|
| | |||||||
| |||||||||
| | ||||||||
Beginner Portfolio Economy | | ||||||||
BUY DATE | SELL DATE | TICKER | BUY PPS | SELL PPS | Gain/Loss | NOTES | % + or - | ||
|
| ||||||||
| | ||||||||
| |||||||||
| |||||||||
| |||||||||
$HEFF LEARNING STATION-LINKS
REAL-TIME Futures Quotes: http://www.sgxniftydowfutureslive.com/index_files/DOWFUTURES.htm …
JANNEY HEALTHCARE NEWSLETTER-http://www.janney.com/institutions--corporations/investment-banking/industry-groups/healthcare/life-sciences-newsletter
Traders: Develop Your Mental Edge by Dr. Andrew Menaker http://j.mp/1phyFIY
Jesse Livermore-Reminiscences Of A Stock Operator-Great Book http://bit.ly/VOObyM
LIFE SCIENCES MARKET : http://www.thelifesciencesreport.com CHMP Decisions Here: http://t.co/7jjqFyn3tx
E-booklet onTrend Determination: A quick accurate and effective methodology using RSI. http://bit.ly/17PmHZ8
The Original Turtle Trading Rules: Rules of the “Turtle Traders;” one of the greatest trading experiments conducted.
http://bit.ly/17jXegf
FAVORITE QUOTES:
"Compounding interest is the eighth wonder of the world. He who understands it, earns it..he who doesn't.. pays it." - Albert Einstein
"Your actions speak so loud I can't hear your words! When that happens, you have found a certain level of success others haven't." Sheff
"IF YOU ARE NOT TAKING YOUR PROFITS, SOMEBODY ELSE IS !" SHEFF
A good name is more desirable than great wealth. Respect is better than silver or gold. -Proverbs 22:1
Don't brag about yourself let others praise you. -Proverbs 27:2
Do not brag about tomorrow, because you do not know what another day may bring. -Proverbs 27:1
One man pretends to be rich, yet has nothing. Another pretends to be poor, yet has great wealth. Proverbs 13:7
You can easily judge the character of a man by how he treats those who can do nothing for him. -James D. Miles
Favorite Sheff Quote: "You can't let praise or criticism get to you. It's a weakness to get caught up in either one." -John Wooden
Favorite Sheff Quote: Talent is God given. Be humble. Fame is man-given. Be grateful. Conceit is self-given. Be careful.
A Trading Plan = Study. A watch-list. Position Sizing. Entries. Exits. Records. Discipline. h/t @sjburns
5 Things I didn't come on twitter to do: Convince anyone of anything , Argue Defend myself Battle Trolls Waste time @sjosephburns
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |